Related Experiment Video
Updated: Apr 27, 2026
08:46
A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
Published on: August 12, 2020
5.5K
Genetic polymorphisms and sepsis in premature neonates
Susanna Esposito1, Alberto Zampiero1, Lorenza Pugni2
1Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Plos One
|July 8, 2014
Summary
Genetic variations in genes like IL1β and MMP-16 increase neonatal sepsis risk, while BPI and DEFβ1 gene variants decrease it. These single nucleotide polymorphisms (SNPs) influence susceptibility and severity in preterm infants.
Area of Science:
- Genetics
- Neonatology
- Infectious Diseases
Background:
- Neonatal sepsis is a significant cause of mortality and morbidity in preterm infants.
- Understanding the genetic factors influencing sepsis susceptibility is crucial for improving outcomes.
- Previous studies suggest a role for genetic polymorphisms in the immune response to pathogens.
Purpose of the Study:
- To investigate the association between single nucleotide polymorphisms (SNPs) in candidate genes and the risk of sepsis in preterm neonates.
- To explore the relationship between specific gene variants and the severity of sepsis, as well as susceptibility to Gram-negative infections.
Main Methods:
- Genotyping of 47 SNPs in 18 candidate genes using ABI PRISM 7900 HT Fast real-time and MassARRAY platforms on Guthrie cards.
- Study included 101 preterm neonates with microbiologically confirmed sepsis, 98 with clinical sepsis, and 100 healthy controls.
- Statistical analysis to determine associations between genotypes and sepsis risk, severity, and pathogen type.
Main Results:
- Specific genotypes of IL1β (rs1143643) and MMP-16 (rs2664349) were linked to increased overall sepsis risk.
- BPI (rs4358188) and DEFβ1 (rs1799946) gene variants were associated with a reduced risk of sepsis.
- CD14 (rs2569190) and IL8 (rs4073) SNPs correlated with increased severe sepsis risk, while LTA (rs1800629) and BPI (rs1341023) variants were associated with Gram-negative sepsis risk.
Conclusions:
- Genetic variability plays a significant role in the susceptibility and severity of sepsis in preterm neonates.
- Identifying specific SNPs can help predict sepsis risk and guide targeted interventions.
- Further research is warranted to elucidate the precise mechanisms by which these genetic factors influence neonatal sepsis.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
156
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
01:27Principles of Pharmacogenetics: Types of Genetic Variants
135
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
135
01:05Single Nucleotide Polymorphisms-SNPs
14.4K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.4K
01:27Pharmacogenetics of Drug Metabolism: Overview
191
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
405
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405